An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk by Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao

Get full text

Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy by Jianyao Zeng, Yan Sun, Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang, Pingjing Zhang, Meiqi Shao, Pei Wang, Jingbo Cheng, Meng Di, Tao Liu, Qijun Qian, Qijun Qian, Qijun Qian

Subjects: Get full text

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno

Subjects: Get full text

CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies by Fang Wang, Ruiqi Zhang, Zhaokai Zhou, Run Shi, Fu Peng, Yudi Xu, Shuai Yang, Zhan Wang, Pengpeng Zhang, Rui Tu, Chun Zhang, Xingchen Liu, Jun Cai

Subjects: Get full text

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma by Jiaying Wu, Wanying Liu, Yang Cao, Yang Yang, Zhen Shang, Mi Zhou, Yicheng Zhang, Fankai Meng, Xiaojian Zhu, Yi Xiao

Get full text

In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma by Zhi Guo, Zhi Guo, Mingxin He, Ning Liu, Yiqing Yang, Rui Sun, Jianxun Wang, Qiang Wang

Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

“…The report underscores the complexities of chimeric antigen receptor T-cell treatment and sheds light on strategies employed to mitigate toxic effects. …”
Get full text

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells by Yang Liu, Xiaoshuang Yuan, Xu Yang, Bo Yang, Guangyang Liu, Xiao Xu, Sanbin Wang, Zhixu He, Feiqing Wang, Yanju Li

Subjects: Get full text

Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment by Liting Chen, Rongshan Huang, Chaoshuo Huang, Guiming Nong, Yuanyuan Mo, Lvyin Ye, Kunhong Lin, Anping Chen, Anping Chen

Subjects: Get full text

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy by Jiawei Wang, Yan Bao, Yandan Yao

“…Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. …”
Get full text

Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example by Ronan Foley, John Kuruvilla

“…Abstract Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). …”
Get full text

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES by Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“… Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. …”
Get full text

The success of the tumor immunotherapy: neutrophils from bench to beside by Meng Zhu, Ru Jia, Xiaojie Zhang, Pingwei Xu

“…The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. …”
Get full text

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and liter... by Xuelian Jin, Zhigang Liu, Yu Wu, Jie Ji

“…Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. …”
Get full text

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis by Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen

“…This study designed the chimeric antigen receptor T-cell (CAR-T) to bind to the CD47 to inhibit the expression of CD47. …”
Get full text

Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis by Nana Zhe, Qiang Li, Nanqu Huang, Hang Li, Hongyun Chen, Pinwei Zhu

“…The current research hotspots of AML immunotherapy included chimeric antigen receptor-T-cell therapy, antibody-based immunotherapies, immune checkpoint blockade, and combination therapy, highlighting the key aspects of immunotherapy for AML treatment and providing comprehensive insights into the research status and advances in this field. …”
Get full text

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma? by Davor Galusic, Ivan Krecak, Viktor Blaslov, Andela Krstulovic Opara, Toni Valkovic, Sandra Basic Kinda

“…Due to the cost and availability of bispecific T cell redirecting antibodies (BsAbs) and chimeric antigen receptor T cell therapy (CAR-T) in real-life settings in many countries, retreatment with daratumumab in subsequent lines of therapy might be a reasonable choice. …”
Get full text

Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer by Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An

“…Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. …”
Get full text

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

“…Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”
Get full text